Management of acute cellular rejection after pediatric heart transplantation

Area of Science:

• Pediatric Cardiology
• Transplant Immunology
• Immunosuppression Management

Background:

• Acute cellular rejection (ACR) is a primary cause of graft injury in pediatric heart transplantation.
• ACR can lead to chronic graft dysfunction, cardiac allograft vasculopathy, antibody-mediated rejection, and mortality.
• Understanding ACR risks, particularly immunosuppression adherence, is vital for mitigating its impact.

Purpose of the Study:

• To review the impact of ACR on pediatric heart transplant outcomes.
• To emphasize risk factors, screening, diagnosis, and management of ACR.
• To highlight strategies for improving transplant recipient outcomes.

Main Methods:

• Review of current literature on acute cellular rejection in pediatric heart transplantation.
• Discussion of diagnostic modalities, including endomyocardial biopsy and non-invasive screening methods.
• Analysis of management strategies based on rejection severity.

Main Results:

• Endomyocardial biopsy is the gold standard for ACR diagnosis.
• Non-invasive methods like gene expression profiling and donor-derived cell-free DNA aid in risk stratification.
• Treatment for severe ACR involves corticosteroids, anti-thymocyte globulin, and hemodynamic support.

Conclusions:

• Effective prevention, early detection, and timely treatment of ACR are essential for enhancing survival and graft function in pediatric heart transplant recipients.
• Continued research into non-invasive screening and optimized immunosuppression is necessary.
• Multifaceted approaches are key to improving long-term outcomes.